Generic versions of Pfizer’s Paxlovid to be sold in low-income countries for $25 or less – National | Globalnews.ca


A number of generic drugmakers that can produce variations of Pfizer’s PFE.N COVID-19 antiviral therapy Paxlovid have agreed to promote the medication in low- and middle-income international locations for $25 a course or much less, the Clinton Well being Entry Initiative (CHAI) stated on Thursday.

CHAI stated it couldn’t disclose the names of the producers who’ve agreed to the value ceiling, as a result of they’re nonetheless within the early stage of product improvement and haven’t acquired regulatory approval.

Learn extra:

Some report COVID symptoms after taking Pfizer’s Paxlovid. Here’s what we know

In March, 35 generic drugmakers around the globe signed on to make low-cost variations of Pfizer’s drugs for 95 poorer international locations by a licensing association with the U.N.-backed Medicines Patent Pool (MPP).

Pfizer sells Paxlovid to the U.S. authorities for about $530 for a five-day course.

Story continues under commercial

CHAI stated the generic drugmakers would dedicate capability for 4.5 million therapy programs a month for these international locations. It stated the $25 worth ceiling would apply provided that there’s demand from the poorer international locations for a minimum of 1 million therapy programs a 12 months.

To be able to assure the value, orders have to be for a minimum of 50,000 programs, it stated.

The Clinton Well being Entry Initiative stated it additionally plans to work with donors and governments to boost funds for an advance buy settlement for the product to fulfill nation wants.


Click to play video: 'Oral COVID-19 medicine Paxlovid will be for certain groups in initial rollout'




Oral COVID-19 drugs Paxlovid will likely be for sure teams in preliminary rollout


Oral COVID-19 drugs Paxlovid will likely be for sure teams in preliminary rollout – Feb 3, 2022

Paxlovid has turn into an vital instrument within the combat in opposition to COVID-19. In a scientific trial, it decreased hospitalizations in high-risk sufferers by round 90% when taken for 5 days shortly after signs start.

The outcomes have been considerably higher than for Merck & Co’s MRK.N rival antiviral capsule molnupiravir in its scientific trial.

Story continues under commercial

Nonetheless, as Paxlovid has turn into extra broadly used, some sufferers have reported a recurrence of COVID-19 signs after finishing the therapy and experiencing enchancment.

A generic course of molnupiravir is anticipated to price about $20 in poorer nations, in contrast with the roughly $700 per course Merck is charging the USA.

— Reporting by Michael Erman


Leave a Comment